How Scientists Are Learning to Reverse Cardiovascular Aging: From Centenarian Genes to Rapamycin

The Heart Ages Faster Than You Think. New Science Suggests It Doesn’t Have To.

Cardiovascular disease remains the leading cause of death worldwide, claiming an estimated 17.9 million lives every year according to the World Health Organization. For decades, the clinical focus has been on managing risk factors: lowering cholesterol, controlling blood pressure, prescribing statins and blood thinners. These interventions save lives. But they do not address a deeper question that a new generation of researchers is now confronting head on: can we actually reverse the aging of the heart itself?

Presented By Our Partners

A cluster of recent studies, published across top journals including GeroScience, Signal Transduction and Targeted Therapy, and Ageing Research Reviews, suggests that the answer may be yes. From a longevity gene found in centenarians that appears to rewind the heart’s biological clock by a decade, to a repurposed immunosuppressant that measurably improved cardiac function in elderly men within just eight weeks, the science of cardiovascular rejuvenation is no longer confined to animal models. It is entering human trials.

This article examines five converging lines of research that, taken together, paint a picture of cardiovascular aging as something far more malleable than previously understood. Each finding reinforces a central theme: the heart does not simply wear out. It is aged by specific molecular processes, and those processes can be targeted, slowed, and in some cases reversed.

A Centenarian’s Gene That Rewinds the Heart by Ten Years

The most striking finding in recent cardiovascular aging research involves a genetic variant called LAV-BPIFB4, identified through genome-wide studies of Italian, American, and German centenarians. Researchers at the Bristol Heart Institute and IRCCS MultiMedica in Milan, led by Paolo Madeddu and Annibale Puca, have spent years investigating why this variant appears at elevated frequency in people who live past 100 while remaining relatively rare in the general population.

Their latest study, published in Signal Transduction and Targeted Therapy in September 2025, demonstrated that delivering the LAV-BPIFB4 gene via an adeno-associated virus vector (AAV9) to progeria mice, a model of accelerated aging, prevented diastolic dysfunction and reduced cellular senescence in heart tissue. The treated mice showed measurable improvements in cardiac relaxation, the phase of the heartbeat cycle most vulnerable to aging. Earlier work by the same group had shown that expressing this gene in naturally aged mice produced cardiac improvements equivalent to reversing the heart’s biological age by approximately ten years in human terms.

The mechanism appears to work through two primary pathways. First, LAV-BPIFB4 promotes angiogenesis, the formation of new blood vessels, restoring nutrient and oxygen delivery to aging cardiac tissue. Second, it reduces the accumulation of senescent cells in the vasculature, those zombie-like cells that have stopped dividing but continue to secrete inflammatory signals that damage surrounding tissue. The combination of improved blood supply and reduced inflammatory burden amounts to a genuine rejuvenation of the cardiac microenvironment.

What makes this research especially compelling is that it is not a synthetic drug or an engineered molecule. It is a naturally occurring human genetic variant that evolution has already selected for in populations that demonstrate exceptional longevity. The therapeutic strategy essentially borrows from biology’s own playbook.

Rapamycin: An Old Drug With a New Cardiac Future

Rapamycin has been a fixture in longevity research for over a decade, primarily studied in animal models where it consistently extends lifespan across species from yeast to mice. Originally developed as an immunosuppressant for organ transplant recipients, rapamycin works by inhibiting mTOR (mechanistic target of rapamycin), a nutrient-sensing pathway that, when chronically activated, drives many hallmarks of aging including cellular hypertrophy, impaired autophagy, and fibrotic tissue remodeling.

What has been missing, until recently, is direct evidence that rapamycin improves cardiovascular function in human beings. A proof-of-concept pilot study led by Dean Kellogg and colleagues at the Barshop Institute at the University of Texas Health Science Center at San Antonio, published in GeroScience in 2025, provided exactly that evidence.

The study enrolled six men aged 70 to 76 with no known cardiac disease. Each received 1 milligram of rapamycin daily for eight weeks. Cardiac MRI was performed before and after treatment. The results were remarkably consistent across all six subjects: transmitral blood flow improved significantly (p = 0.033), peak filling rate increased (p = 0.014), and maximal blood acceleration showed the strongest improvement (p = 0.004). Endothelial function, measured through laser Doppler flowmetry of skin blood flow responses, also improved over the treatment period.

These are not marginal changes. Diastolic dysfunction, the impaired relaxation of the heart between beats, is the earliest and most common form of age-related cardiac decline. It affects more than half of adults over 60 and is the dominant mechanism behind heart failure with preserved ejection fraction (HFpEF), a condition with no approved pharmacological treatment. The fact that a low-dose, short-term course of rapamycin measurably improved diastolic parameters in healthy older men opens a significant therapeutic window.

The study’s authors note that chronic mTOR signaling promotes cardiomyocyte hypertrophy, impairs mitochondrial turnover via suppressed autophagy, and accelerates fibrotic remodeling of the myocardium. Rapamycin appears to restore the balance by reactivating autophagy, the cellular housekeeping process that clears damaged proteins and organelles, and by dampening the low-grade chronic inflammation that characterizes cardiac aging. The researchers are now planning placebo-controlled studies in larger cohorts, including patients with established diastolic dysfunction.

Blood Flow, Brown Fat, and the Vascular Key to Longevity

A comprehensive review published in Ageing Research Reviews in early 2026 by Stephen Vatner’s group at Rutgers New Jersey Medical School brings an underappreciated mechanism to the center of the longevity conversation: blood flow and angiogenesis.

The review examined 25 rodent models of healthful longevity, models in which animals not only lived longer but maintained better organ function and exercise capacity into old age. Seven of these models showed direct evidence that improved blood flow and enhanced angiogenesis were key mediators of their longevity advantage. The mechanisms underlying this improvement included not only well-known vascular growth factors and mitochondrial protection but also a surprising contributor: brown adipose tissue (BAT).

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Brown fat, once thought to be relevant only in infants and hibernating animals, has emerged in recent years as a metabolically active tissue in adult humans. The Vatner group highlighted a particularly illustrative model: the Regulator of G Protein Signaling 14 (RGS14) knockout mouse, which exhibits dramatically increased angiogenesis and blood flow. When the researchers surgically removed brown adipose tissue from these mice, the vascular improvements vanished. When they transplanted brown adipose tissue into normal wild-type mice, blood flow and angiogenesis improved.

This finding suggests that brown fat is not merely a calorie-burning tissue. It appears to function as a signaling hub that promotes vascular health and, through improved blood flow, supports the function of downstream organs including the heart, brain, and kidneys. As human lifespan extends but healthspan lags behind, the vascular system may represent the rate-limiting step. If blood flow declines, every organ suffers. Restoring angiogenic capacity, whether through brown fat activation, exercise, or pharmacological intervention, may be one of the most powerful levers for extending functional years of life.

SIRT5: The Cardiac Sirtuin You Haven’t Heard Of

The sirtuin family of proteins, particularly SIRT1 and SIRT3, has received enormous attention in aging research. But a 2025 review published in GeroScience by Arkadiusz Grzeczka and colleagues at Nicolaus Copernicus University argues that SIRT5 may be the most important sirtuin for cardiac health specifically, and that it has been dramatically understudied.

SIRT5 is unique among sirtuins in its enzymatic activity. While most sirtuins primarily deacetylate proteins, SIRT5 removes succinyl, malonyl, and glutaryl groups from lysine residues, modifications that profoundly affect mitochondrial metabolism. Given that the heart is the most mitochondria-dense organ in the body, consuming more oxygen per gram than any other tissue, SIRT5’s role in maintaining mitochondrial quality control is directly relevant to cardiac aging.

The review synthesizes evidence that SIRT5 modulates fatty acid oxidation (the heart’s preferred fuel source), regulates oxidative stress responses, and influences apoptotic signaling pathways. In animal models, SIRT5 deficiency leads to increased susceptibility to ischemia-reperfusion injury, accelerated cardiac hypertrophy, and worsened diabetic cardiomyopathy. Conversely, SIRT5 activation appears to protect against these conditions.

The complexity lies in the fact that SIRT5’s effects are highly context-dependent. In certain cancer models, SIRT5 activation can be harmful, promoting tumor cell metabolism. For cardiac aging specifically, however, the evidence consistently points toward SIRT5 as a protective factor whose decline with age contributes to the metabolic inflexibility and mitochondrial dysfunction that characterize the aging heart.

The therapeutic implication is that strategies to maintain or restore SIRT5 activity, whether through NAD+ precursor supplementation (SIRT5, like all sirtuins, depends on NAD+ as a cofactor), caloric restriction mimetics, or targeted small molecules, could offer a new axis for cardiovascular protection that operates independently of traditional lipid and blood pressure management.

Inflamm-Aging and the Immune Clock of the Heart

A 2026 study published in Reviews in Cardiovascular Medicine by researchers at Sun Yat-sen University adds a crucial immunological dimension to the cardiovascular aging picture. The study, which followed 1,274 hospitalized patients with heart failure with preserved ejection fraction (HFpEF) over a median of 4.9 years, found that the lymphocyte-to-monocyte ratio (LMR), a simple blood marker of immune balance, partially mediated the relationship between age and cardiovascular death.

Patients in the highest tertile of LMR, those with relatively more lymphocytes and fewer monocytes, had a 77% lower risk of cardiovascular death compared to those in the lowest tertile. More important than the prognostic value was the mechanistic insight: mediation analysis showed that LMR accounted for 17.9% of the effect of age on cardiovascular mortality. In other words, nearly one-fifth of the reason that older patients die from cardiovascular causes can be statistically attributed to the shift in immune cell composition that occurs with aging.

This shift has a name: immunosenescence, accompanied by its partner process, inflamm-aging. As people age, the immune system becomes simultaneously less effective at fighting infections and more prone to generating chronic, low-grade inflammation. The monocyte population expands, producing inflammatory cytokines that drive vascular stiffening, endothelial dysfunction, and myocardial fibrosis. Meanwhile, the lymphocyte population declines, reducing the immune system’s regulatory capacity.

The clinical significance is profound. The LMR is available from a standard complete blood count, making it one of the most accessible biomarkers in all of medicine. If future interventions can shift the immune composition back toward a more youthful balance, whether through senolytics, immune-modulating drugs, exercise programs, or dietary interventions, the downstream cardiovascular benefits could be substantial.

A New Framework for Cardiovascular Longevity

A 2025 review published in Ageing Research Reviews by Chunsong Hu at Nanchang University Hospital proposes a unifying framework for cardiovascular disease prevention and longevity. Called the E(e)SEEDi scoring system, it assigns 20 points each to six core lifestyle and environmental factors: environment, sleep, emotion, exercise, diet, and intervention. A maximum score of 120 reflects optimal engagement across all domains.

The framework is notable not for any single insight but for its attempt to map each lifestyle factor to specific cellular and molecular mechanisms, what the author calls a chain of "mechanisms, hallmarks, and biomarkers." Eight molecular hallmarks are identified as common denominators in cardiovascular aging: disabled macroautophagy, loss of proteostasis, genomic instability (including clonal hematopoiesis of indeterminate potential), epigenetic alterations, mitochondrial dysfunction, cellular senescence, dysregulated neurohormonal signaling, and chronic inflammation.

Each lifestyle domain in the scoring system connects to one or more of these hallmarks. Exercise, for example, activates autophagy, improves mitochondrial biogenesis, and reduces senescent cell burden. Sleep quality modulates neurohormonal signaling and inflammatory markers. Emotional health affects cortisol-mediated epigenetic changes and immune function. Diet influences the gut microbiome, which in turn affects systemic inflammation and metabolic health.

The framework also highlights clonal hematopoiesis of indeterminate potential (CHIP) as a particularly important and underappreciated risk factor for cardiovascular disease. CHIP occurs when a single hematopoietic stem cell acquires a mutation that gives it a growth advantage, leading to an expanded clone of immune cells carrying the mutation. Research over the past five years has established that CHIP, even in the absence of blood cancer, significantly increases the risk of coronary artery disease, heart failure, and cardiovascular death. Its prevalence rises steeply with age, affecting over 10% of adults past 70.

What This Means for You

The convergence of these five research threads carries a clear message: cardiovascular aging is not a fixed trajectory. The molecular processes that stiffen your arteries, impair your heart’s ability to relax between beats, and drive chronic vascular inflammation are not immutable facts of biology. They are targets.

For readers who want to act on the science available today, the evidence points toward several practical strategies.

First, prioritize diastolic health monitoring. Ask your physician about echocardiographic assessment of diastolic function, especially if you are over 50. Diastolic dysfunction precedes symptomatic heart failure by years or even decades, and catching it early opens a window for intervention.

Second, maintain or build your exercise habit with a focus on both aerobic fitness and resistance training. The evidence linking exercise to improved autophagy, mitochondrial function, angiogenesis, and immune balance is among the strongest in all of preventive medicine. The rapamycin study’s improvements in diastolic function closely mirror what regular exercise achieves, suggesting that the pathways overlap significantly.

Third, pay attention to sleep quality and emotional health. The E(e)SEEDi framework underscores what the mechanistic data confirms: poor sleep and chronic psychological stress accelerate every molecular hallmark of cardiovascular aging.

Fourth, ask your doctor about inflammatory markers beyond the standard lipid panel. High-sensitivity C-reactive protein, the neutrophil-to-lymphocyte ratio, and the lymphocyte-to-monocyte ratio are inexpensive tests that provide a window into your immune aging trajectory.

Fifth, watch the clinical pipeline closely. Rapamycin is moving toward larger placebo-controlled cardiovascular trials. Gene therapy approaches based on the BPIFB4 centenarian variant are in preclinical development. SIRT5-targeted interventions and senolytic drugs aimed at clearing senescent vascular cells are in early-stage human trials. The next five to ten years will likely bring the first approved therapies that directly target the biology of cardiovascular aging rather than just its downstream risk factors.

The heart is not destined to fail. It is aged by identifiable, modifiable molecular processes, and the science to address them is further along than most people realize.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.